Impaired calcium handling and mitochondrial metabolic dysfunction as early markers of hypertrophic cardiomyopathy

Abstract excerpt

Hypertrophic cardiomyopathy (HCM) is a primary myocardial disorder, characterised by myocyte remodeling, disorganisation of sarcomeric proteins, impaired energy metabolism and altered cardiac contractility. Gene mutations encoding cardiac contractile proteins account for 60% of HCM aetiology. Current drug therapy including L-type calcium channel antagonists, are used to manage symptoms in patients with overt HCM,...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cardiomyopathy and Myosin Studies
• Share to Cardiovascular Effects of Exercise
• Share to Cardiovascular Function and Risk Factors